NASDAQ:REPL - US76029N1063 - Common Stock
The current stock price of REPL is 6.33 USD. In the past month the price increased by 15.51%. In the past year, price decreased by -38.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.07 | 375.50B | ||
AMGN | AMGEN INC | 13.01 | 152.70B | ||
GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.89 | 40.63B | ||
INSM | INSMED INC | N/A | 30.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
NTRA | NATERA INC | N/A | 23.06B | ||
BIIB | BIOGEN INC | 8.79 | 20.62B |
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 331
Phone: 17812229600
The current stock price of REPL is 6.33 USD. The price increased by 8.95% in the last trading session.
The exchange symbol of REPLIMUNE GROUP INC is REPL and it is listed on the Nasdaq exchange.
REPL stock is listed on the Nasdaq exchange.
15 analysts have analysed REPL and the average price target is 7.29 USD. This implies a price increase of 15.1% is expected in the next year compared to the current price of 6.33. Check the REPLIMUNE GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REPLIMUNE GROUP INC (REPL) has a market capitalization of 494.12M USD. This makes REPL a Small Cap stock.
REPLIMUNE GROUP INC (REPL) currently has 331 employees.
REPLIMUNE GROUP INC (REPL) has a support level at 5.53 and a resistance level at 11.45. Check the full technical report for a detailed analysis of REPL support and resistance levels.
The Revenue of REPLIMUNE GROUP INC (REPL) is expected to grow by 300% in the next year. Check the estimates tab for more information on the REPL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
REPL does not pay a dividend.
REPLIMUNE GROUP INC (REPL) will report earnings on 2025-11-10.
REPLIMUNE GROUP INC (REPL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.24).
The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 25.35% of its float. Check the ownership tab for more information on the REPL short interest.
ChartMill assigns a technical rating of 1 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is a bad performer in the overall market: 95.04% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to REPL. While REPL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS increased by 0.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -59.68% | ||
ROE | -83.22% | ||
Debt/Equity | 0.21 |
15 analysts have analysed REPL and the average price target is 7.29 USD. This implies a price increase of 15.1% is expected in the next year compared to the current price of 6.33.
For the next year, analysts expect an EPS growth of -10.21% and a revenue growth 300% for REPL